A new injectable treatment for two rare types of non-Hodgkin lymphoma
The US Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome after at least one prior systemic therapy. This is the first FDA approval of a drug specifically for Sézary syndrome.
To continue reading this article
Continue reading your article with a eMediNexus account.